• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CellCentric selects Sygnature Discovery for epigenetic prostate cancer program

CellCentric selects Sygnature Discovery for epigenetic prostate cancer program

September 9, 2013
CenterWatch Staff

Sygnature Discovery, a provider of integrated drug discovery services, has been selected by CellCentric, a biotechnology company with a scientific foundation in epigenetics, to progress small molecule inhibitor drug discovery against a specific deubiquitinase (DUB) enzyme which has been demonstrated to play a key role in the progression of prostate cancer.

CellCentric recently received $6.7 million through further venture investment and an award from the U.K. government-backed Technology Strategy Board’s BioMedical Catalyst Fund to further fuel the DUB program through to small molecule clinical candidates.  The new agents act upon the androgen receptor (AR) pathway, which is gaining interest from the pharmaceutical industry. CellCentric’s approach has the potential to modulate AR and AR splice variants, which could be key to overcoming many of the drug resistance mechanisms that limit the clinical benefit of existing approved and developmental therapeutic agents.

Dr. Simon Hirst, chief executive officer, Sygnature Discovery, said, “Epigenetics is a rapidly evolving field and this is an opportunity for us to work on an unexplored and challenging drug target.  Sygnature has considerable in-house oncology drug discovery knowledge and having medicinal chemistry, computational chemistry and in vitro screening under one roof will enable us to accelerate CellCentric’s prostate cancer program toward the clinic.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing